EUROIMMUN, a PerkinElmer company, announces the launch of the European Conformity (CE)-marked EURORealTime SARS-CoV-2/Influenza A/B PCR test for direct detection of SARS-CoV-2, influenza virus type A, and influenza virus type B. It expands the testing portfolio for acute COVID-19 diagnostics by supporting differential diagnostics between SARS-CoV-2 infections and the common flu, and is available in countries accepting the CE mark. PCR technology is considered the gold standard for direct pathogen detection. The EURORealTime test allows fast detection and differentiation of genetic material using throat-swab samples of patients with acute symptoms. Validation efforts revealed high agreement of results obtained with the EURORealTime test and those obtained with reference PCR tests for SARS-CoV-2 and influenza A/B. No cross-reactions with other common respiratory pathogens were detected. The assay is compatible with common real-time PCR thermal cyclers, and the EURORealTime Analysis Software allows for reliable, standardized evaluation of test results.